Preferred Label : Atezolizumab;
NCIt synonyms : MPDL328OA; MPDL 328OA; Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy
Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer;
NCIt definition : A humanized, Fc optimized, monoclonal antibody directed against the protein ligand
PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint
inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its
binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed
on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms
and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also
prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which
further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many
human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding
to PD-1 on T-cells suppresses the immune system and results in increased immune evasion.
PD-1, a transmembrane protein, is a negative regulator of the immune system that limits
the expansion and survival of CD8 T cells. The Fc region of atezolizumab is modified
in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC)
or complement-dependent cytotoxicity (CDC).;
UNII : 52CMI0WC3Y;
CAS number : 1380723-44-3;
Drug name : Tecentriq;
Molecule name : MPDL-3280A; MPDL 3280A; RO-5541267; RG-7446; RG 7446; RO 5541267;
Codes from synonyms : 49;
Origin ID : C106250;
UMLS CUI : C4055433;
Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
